p53-associated differential response to platinumgemcitabine and platinum-paclitaxel in advanced nonsmall cell lung cancer

1. Schrump DS AN, Henschke CL, Carter D, Turris AT, Gutierrez. Cancer: Principle and practice of oncology. Philadelphia: Lippincott William & Wilkins; 2005.Search in Google Scholar

2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346:92-8.10.1056/NEJMoa011954Search in Google Scholar

3. Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002; 20: 4285-91.10.1200/JCO.2002.02.068Open DOISearch in Google Scholar

4. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science. 1994; 266:807-10.10.1126/science.7973635Search in Google Scholar

5. O’Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997; 57:4285-300.Search in Google Scholar

6. Gregorc V, Ludovini V, Pistola L, Darwish S, Floriani I, Bellezza G, et al. Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer. 2003; 39:41-8.10.1016/S0169-5002(02)00391-4Search in Google Scholar

7. Kawasaki M, Nakanishi Y, Kuwano K, Takayama K, Kiyohara C, Hara N. Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer. Eur J Cancer. 1998; 34: 1352-7.10.1016/S0959-8049(98)00067-7Search in Google Scholar

8. Kawasaki M, Nakanishi Y, Kuwano K, Yatsunami J, Takayama K, Hara N. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer. Clin Cancer Res. 1997; 3:1195-200.Search in Google Scholar

9. Galmarini CM, Clarke ML, Falette N, Puisieux A, Mackey JR, Dumontet C. Expression of a nonfunctional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer. 2002; 97:439-45.10.1002/ijc.1628Search in Google Scholar

10. Chen M, Hough AM, Lawrence TS. The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization. Cancer Chemother Pharmacol. 2000; 45:369-74.10.1007/s002800051004Search in Google Scholar

11. Safran H, King T, Choy H, Gollerkeri A, Kwakwa H, Lopez F, et al. p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma. Cancer. 1996; 78:1203-10.10.1002/(SICI)1097-0142(19960915)78:6<1203::AID-CNCR6>3.0.CO;2-ASearch in Google Scholar

12. King TC, Akerley W, Fan AC, Moore T, Mangray S, Hsiu Chen M, et al. p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma. Cancer. 2000; 89:769-73.10.1002/1097-0142(20000815)89:4<769::AID-CNCR8>3.0.CO;2-6Search in Google Scholar

13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92:205-16.10.1093/jnci/92.3.205Open DOISearch in Google Scholar

14. Gajra A, Tatum AH, Newman N, Gamble GP, Lichtenstein S, Rooney MT, et al. The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer. Lung Cancer. 2002; 36: 159-65.10.1016/S0169-5002(01)00463-9Search in Google Scholar

15. Johnson EA, Klimstra DS, Herndon JE, 2nd, Catalano E, Canellos GP, Graziano SL, et al. Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer. Cancer Invest. 2002; 20:686-92.10.1081/CNV-120003537Open DOISearch in Google Scholar

16. Korobowicz E, Zdunek M. Immunohistochemical study of p53 in non-small cell lung cancer before and after preoperative chemotherapy. Pol J Pathol. 2000; 51:71-6.Search in Google Scholar

17. Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res. 1995; 55:5038-42.Search in Google Scholar

18. Joerger M, deJong D, Burylo A, Burgers JA, Baas P, Huitema AD, et al. Tubuline, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy. Lung Cancer. 2011; 74:310-7.10.1016/j.lungcan.2011.03.016Search in Google Scholar

19. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994; 54:4855-78.Search in Google Scholar

20. Soussi T, Lozano G. p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun. 2005; 10; 331: 834-42.10.1016/j.bbrc.2005.03.190Search in Google Scholar

21. Carbone DP, Mitsudomi T, Chiba I, Piantadosi S, Rusch V, Nowak JA, et al. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest. 1994; 106(6 Suppl):377S-81S.10.1378/chest.106.6.377SSearch in Google Scholar

22. Bernardini S, Adessi GL, Billerey C, Chezy E, Carbillet JP, Bittard H. Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas. J Urol. 1999; 162:1496-501.10.1016/S0022-5347(05)68347-4Search in Google Scholar